Axsome Therapeutics, Inc. (AXSM)
Automate Your Wheel Strategy on AXSM
With Tiblio's Option Bot, you can configure your own wheel strategy including AXSM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AXSM
- Rev/Share 11.2204
- Book/Share 1.4739
- PB 93.4937
- Debt/Equity 2.9311
- CurrentRatio 1.5691
- ROIC -0.5573
- MktCap 6946856280.0
- FreeCF/Share -2.0118
- PFCF -69.0316
- PE -30.0314
- Debt/Assets 0.3229
- DivYield 0
- ROE -3.5721
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AXSM | B. Riley Securities | -- | Buy | -- | $179 | Oct. 1, 2025 |
| Resumed | AXSM | Wells Fargo | -- | Overweight | -- | $163 | Sept. 3, 2025 |
| Resumed | AXSM | Morgan Stanley | -- | Overweight | -- | $190 | July 3, 2025 |
| Initiation | AXSM | Oppenheimer | -- | Outperform | -- | $185 | June 3, 2025 |
| Initiation | AXSM | Jefferies | -- | Buy | -- | $200 | April 7, 2025 |
| Initiation | AXSM | Deutsche Bank | -- | Buy | -- | $176 | Feb. 11, 2025 |
| Reiterated | AXSM | Mizuho | -- | Outperform | $124 | $122 | Dec. 31, 2024 |
| Initiation | AXSM | Wells Fargo | -- | Overweight | -- | $140 | Sept. 3, 2024 |
News
Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Positive
Axsome Therapeutics remains a 'Sell' due to an undifferentiated CNS pipeline, heavy SG&A, and ongoing net losses despite revenue growth. Auvelity's sales growth appears largely marketing-driven and competes in a crowded, generic-heavy depression market. AXS-05 for Alzheimer's agitation offers some promise as a non-antipsychotic, but real-world adoption and blockbuster potential are limited.
Read More
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
Read More
Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
Published: November 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Axsome Therapeutics, Inc. ( AXSM ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Darren Opland - Director of Corporate Communications Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Ari Maizel - Chief Commercial Officer Mark Jacobson - Chief Operating Officer Conference Call Participants Leonid Timashev - RBC Capital Markets, Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Sean Laaman - Morgan Stanley, Research Division Ashwani Verma - UBS Investment Bank, Research Division Lin Tsai - Jefferies LLC, …
Read More
Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Published: October 24, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. If you currently own Axsome stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about yo.
Read More
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
Read More
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstructive sleep apnea Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstructive sleep apnea
Read More
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Read More
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Read More
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September:
Read More
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings
Published: August 05, 2025 by: Benzinga
Sentiment: Positive
Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday.
Read More
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Read More
Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript
Published: August 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Asim Rana - Truist Securities, Inc., Research Division David A. Amsellem - Piper Sandler & Co., Research Division David Timothy Hoang - Deutsche Bank AG, Research Division Graig C.
Read More
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1.24 per share a year ago.
Read More
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file AXS-14 and Sunosi's failure in MDD studies, but ADHD data for Sunosi is encouraging. I estimate $3bn in peak revenues by the mid-2030s, which supports a Buy rating despite management's more ambitious projections.
Read More
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses
Read More
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Read More
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competitive depression market, but its success is heavily reliant on aggressive marketing and significant spending. Upcoming launches and regulatory submissions for Symbravo, AXS-14, AXS-05, and AXS-12 face stiff competition and potential regulatory hurdles.
Read More
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Read More
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason …
Read More
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Published: May 05, 2025 by: Benzinga
Sentiment: Positive
Axsome Therapeutics Inc AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.
Read More
Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago.
Read More
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming investor conferences in May:
Read More
Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached their fiduciary duties to shareholders.
Read More
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Read More
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
Published: April 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 8, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Axsome caused the company to misrepresent or fail to disclose (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the …
Read More
About Axsome Therapeutics, Inc. (AXSM)
- IPO Date 2015-11-19
- Website https://www.axsome.com
- Industry Biotechnology
- CEO Herriot Tabuteau
- Employees 712